Celgene appoints new Haematology head
pharmafile | April 15, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene, browne
Celgene has announced the appointment of Karen Browne as business unit director of Haematology, Celgene UK and Ireland.
Over the past 15 years, Karen has held various sales, sales management and marketing positions in a number of companies, including Innovex UK and Nycomed UK.
Browne first joined Celgene in 2008 as product manager in the UK and Ireland. During her time in this role, she built-up Celgene’s myelodysplastic syndrome (MDS) franchise. Relocating to Switzerland in March 2010 she took up the role of associate director of MDS and acute myeloid leukaemia (AML). Less than two years later, in January 2012, Karen was promoted to director with responsibility for overall MDS/AML marketing across Europe.
Karen said: “I am excited to rejoin the UK team in my new role as Business Unit director of Haematology. I look forward to continuing to work in an area that I am passionate about and to having the opportunity to build on the life-changing work that is already being undertaken by Celgene.”
Samantha Pearce, general manager of Celgene UK and Ireland, added: “This new appointment will enable Karen to bring together her prior sales management and marketing experience to lead the unit. In her previous roles at Celgene, Karen has proven to be a passionate, committed and resourceful leader with the ability to inspire and motivate teams. The expertise Karen will bring from her European role will help us to improve the support we are able to provide people living with these rare diseases in the UK.”
Related Content
NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …
